Placebo + AMG 301
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Migraine or Episodic Migraine
Conditions
Chronic Migraine or Episodic Migraine
Trial Timeline
Sep 6, 2017 → Feb 4, 2019
NCT ID
NCT03238781About Placebo + AMG 301
Placebo + AMG 301 is a phase 2 stage product being developed by Amgen for Chronic Migraine or Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT03238781. Target conditions include Chronic Migraine or Episodic Migraine.
What happened to similar drugs?
20 of 20 similar drugs in Chronic Migraine or Episodic Migraine were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03238781 | Phase 2 | Completed |
Competing Products
20 competing products in Chronic Migraine or Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Levofloxacin 500 | Dr. Reddy's Laboratories | Pre-clinical | 23 |
| mRNA-0184 | Moderna | Phase 1 | 0 |
| Lubiprostone + Lubiprostone + Placebo | Dr. Reddy's Laboratories | Phase 3 | 37 |
| macitentan 10 mg | BML, Inc. | Phase 3 | 32 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 29 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 36 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 23 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 35 |
| THB001 | Third Harmonic Bio | Phase 1 | 11 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 26 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 14 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 29 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 40 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 29 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 44 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 35 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 42 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 21 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 27 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 25 |